These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11741223)

  • 21. Vampire bat salivary plasminogen activator evokes minimal bleeding relative to tissue-type plasminogen activator as assessed by a rabbit cuticle bleeding time model.
    Mellott MJ; Ramjit DR; Stabilito II; Hare TR; Senderak ET; Lynch JJ; Gardell SJ
    Thromb Haemost; 1995 Mar; 73(3):478-83. PubMed ID: 7545321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator.
    Shenkman B; Livnat T; Budnik I; Tamarin I; Einav Y; Martinowitz U
    Blood Coagul Fibrinolysis; 2012 Dec; 23(8):729-33. PubMed ID: 22918041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
    Wu JH; Diamond SL
    J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.
    Lourenço DM; Dosne AM; Kher A; Samama M
    Thromb Haemost; 1989 Nov; 62(3):923-6. PubMed ID: 2556812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibrin targeting of echogenic liposomes with inactivated tissue plasminogen activator.
    Klegerman ME; Zou Y; McPherson DD
    J Liposome Res; 2008; 18(2):95-112. PubMed ID: 18569446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current status of activity assays for tissue plasminogen activator.
    Tang JC; Li S; McGray P; Vecchio A
    Ann N Y Acad Sci; 1984; 434():536-40. PubMed ID: 6441502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum albumin-protamine conjugate for biocompatible platform for targeted delivery of therapeutic macromolecules.
    Absar S; Nahar K; Choi S; Ahsan F; Yang VC; Kwon YM
    J Biomed Mater Res A; 2014 Aug; 102(8):2481-90. PubMed ID: 23946132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo.
    Runge MS; Bode C; Matsueda GR; Haber E
    Proc Natl Acad Sci U S A; 1987 Nov; 84(21):7659-62. PubMed ID: 3118374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
    Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
    Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hybrid molecules: insights into plasminogen activator function.
    Runge MS; Bode C; Haber E; Quertermous T
    Mol Biol Med; 1991 Apr; 8(2):245-55. PubMed ID: 1806766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bio-responsive delivery of tissue plasminogen activator for localized thrombolysis.
    Absar S; Kwon YM; Ahsan F
    J Control Release; 2014 Mar; 177():42-50. PubMed ID: 24417965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clot lysis mediated by cultured human microvascular endothelial cells.
    Speiser W; Anders E; Binder BR; Müller-Berghaus G
    Thromb Haemost; 1988 Dec; 60(3):463-7. PubMed ID: 3149047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heparin-triggered release of camouflaged tissue plasminogen activator for targeted thrombolysis.
    Absar S; Choi S; Yang VC; Kwon YM
    J Control Release; 2012 Jan; 157(1):46-54. PubMed ID: 21930168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Post-thrombolysis haemostasis changes after rt-PA treatment in acute cerebral infarct. Correlations with cardioembolic aetiology and outcome.
    Sun X; Berthiller J; Derex L; Trouillas P; Diallo L; Hanss M
    J Neurol Sci; 2015 Feb; 349(1-2):77-83. PubMed ID: 25619569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effector roles of kringle 1 and kringle 2 in the enzymatic properties of recombinant tissue-type plasminogen activator as revealed by generation of recombinant molecules containing each kringle linked to the protease domain.
    Rydzewski A; Castellino FJ
    Arch Biochem Biophys; 1993 Jan; 300(1):472-82. PubMed ID: 8424682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of pro-urokinase and urokinase on the fibrinolytic system in man.
    Trübestein G; Popov S; Wolf H; Welzel D
    Haemostasis; 1987; 17(4):238-44. PubMed ID: 2442078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Fibrinogen-Mimicking, Activated-Platelet-Sensitive Nanocoacervate Enhances Thrombus Targeting and Penetration of Tissue Plasminogen Activator for Effective Thrombolytic Therapy.
    Huang Y; Jiang J; Ren J; Guo Y; Zhao Q; Zhou J; Li Y; Chen R
    Adv Healthc Mater; 2022 Oct; 11(19):e2201265. PubMed ID: 35864062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Southern copperhead venom enhances tissue-type plasminogen activator induced fibrinolysis but does not directly lyse human plasma thrombi.
    Nielsen VG
    J Thromb Thrombolysis; 2016 Jul; 42(1):33-7. PubMed ID: 26407681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Absence of inhibition by lipoprotein (a) inhibition of tPA induced thrombolysis in a patient's plasma milieu.
    Lu H; Bruckert J; Soria J; Li H; de Gennes JL; Legrand A; Peynet J; Soria C
    Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):513-6. PubMed ID: 1966796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.
    Pannell R; Li S; Gurewich V
    J Thromb Thrombolysis; 2017 Aug; 44(2):210-215. PubMed ID: 28600623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.